Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0528 • ACR Convergence 2025
Apolipoprotein A1 and B Levels Indicate Specific Lipid Changes In Early Treatment Naïve Psoriatic Arthritis and Correlate With 1-year Disease Activity
Alla Ishchenko¹, Margot Van Mechelen², Barbara Neerinkx¹, Patrick Verschueren³, Rik Lories¹ and Kurt de Vlam⁴, ¹KU Leuven, Leuven, Belgium, ²UZA Antwerp, Antwerp, Belgium, ³Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁴KU Leuven, UZ Gasthuisberg, Leuven, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is associated with increased cardiovascular risk and a pro-atherogenic lipid profile. We hypothesize that alterations in lipid metabolism combined with systemic…
Abstract Number: 0556 • ACR Convergence 2025
Evaluating the Efficacy of Sulfasalazine Compared to Placebo in the Treatment of Psoriatic Arthritis in Adults: A Systematic Review and Meta-Analysis
Rameez Qasim¹, Khadija Mohib², Umme Abeeha Naqvi³, Ahmad Furqan Anjum⁴ and Moeeza Fatima⁴, ¹Allama Iqbal Medical College Lahore, Lahore, Pakistan, ²Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ³Jinnah Sindh Medical University Karachi, Karachi, Pakistan, ⁴Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Shaikh Zayed Postgraduate Medical Institute (SZPGMI), Lahore, Lahore, Pakistan
Background/Purpose: Available evidence hints towards the positive results of the use of sulfasalazine in the management of patients with psoriatic arthritis (PsA). We did a…
Abstract Number: 0580 • ACR Convergence 2025
Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Melissa Eliot², Robert Low³ and Alexis Ogdie⁴, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic disease that causes inflammation of the joints, entheses, spine, skin, and nails.1 While available advanced treatments (txs) for…
Abstract Number: 1241 • ACR Convergence 2025
Beyond Pain Severity in Psoriatic Arthritis: Pain Catastrophizing Independently Impacts Disease Burden and Quality of Life
Kyra Chen¹, Uma Scher² and Rebecca Haberman³, ¹NYU Grossman School of Medicine and NYU Langone Health Psoriatic Arthritis Center, New York, ²NYU School of Medicine, Scarsdale, NY, ³NYU Langone Health, New York, NY
Background/Purpose: Pain remains a major burden in psoriatic arthritis (PsA), often persisting despite effective control of synovial inflammation. This persistent pain may prevent patients from…
Abstract Number: 1439 • ACR Convergence 2025
Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
Vassiliki Poulia¹, Eleni Sampatakaki², Dimitrios Katsifis-Nezis³, Maria Pappa³, Evangelia Mole⁴, Sousana Gazi⁴, Elpida Skouvaklidou⁵, Nikolaos Kougkas⁵, Maria Polyzou⁶, Loukia Koutsogeorgopoulou⁶, Ioannis Xynogalas⁷, Anastasios Karamanakos⁷, Konstantinos D Vassilakis¹, Evangelos Papadimitriou⁸, Charalampos Papagoras⁸, Gerasimos Evangelatos⁹, Nafsika Gerolymatou¹⁰, Paraskevi V Voulgari¹⁰ and George E Fragoulis¹, ¹First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ²Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Attiki, Greece, ³Rheumatology and Clinical Immunology Unit, ⁴th Department of Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ⁴Rheumatology department, KAT General Hospital of Attica, Athens, Attiki, Greece, ⁵⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ⁶Department of Pathophysiology, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ⁷Department of Rheumatology, Evangelismos General Hospital, Athens, Attiki, Greece, ⁸First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece, ⁹Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Attiki, Greece, ¹⁰Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece
Background/Purpose: Bimekizumab, a dual IL-17 A and F blocker, has recently been added in the therapeutic rheumatologist’s armamentarium of PsA, but real-world evidence is lacking.…
Abstract Number: 1710 • ACR Convergence 2025
Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level
Andre Lucas Ribeiro¹, Sibel Aydin², Gurjit Kaeley³, Fahmeen J. Afgani⁴, Catherine Bakewell⁵, Marcos Rosemffet⁶, Minna Kohler⁷, Amir Haddad⁸, Maria S. Stoenoiu⁹, Ari Polachek¹⁰, josefina marin¹¹, Arnon Katz¹², Sahil Koppikar¹³ and Lihi Eder¹⁴, ¹Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³UF COM-J, Ponte Vedra Beach, FL, ⁴Women's College Hospital, Toronto, Canada, ⁵Intermountain Healthcare, Salt Lake City, UT, ⁶Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ⁷Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁸Carmel Medical Centre, Haifa, Israel, ⁹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁰Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel, ¹¹Hospital Universitario Rey Juan Carlos, Madrid, Spain, ¹²GRAPPA, Seattle, ¹³Women's College Hospital & University of Toronto, Markham, ON, Canada, ¹⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Enthesitis affects 30–40% of PsA patients but remains difficult to diagnose due to overlap with non-specific entheseal pain. While OMERACT has standardized ultrasound (US)…
Abstract Number: 2036 • ACR Convergence 2025
JAK1 selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis
LETICIA LEON¹, Pedro Pablo Bermejo², Leonor Laredo³, José Alberto Peña⁴, María Teresa Benítez⁵, DALIFER FREITES⁶, CLARA DE MIGUEL³ and lydia Abasolo Alcazar⁷, ¹Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, ²Clinical Pharmacology Service, San Carlos Clinical Hospital, MADRID, Madrid, Spain, ³Hospital Clinico San Carlos, MADRID, Madrid, Spain, ⁴Pharmacy Service San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁵San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁶Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁷IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Janus kinase inhibitors (JAKis) are effective therapeutic agents against chronic inflammatory arthritis (CIA). Tofacitinib and baricitinib were defined as pan-JAK inhibitors, while upadacitinib and…
Abstract Number: 2332 • ACR Convergence 2025
Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44
Dafne capelusnik¹, Clementina López Medina², Désirée Van Der Heijde³, Daniel Aletaha⁴, Josef Smolen⁵, Anna Molto⁶ and Sofia Ramiro⁷, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Medical University Vienna, Wien, Austria, ⁵Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁶Assistance Publique Hôpitauxde Paris, Paris, France, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Recent studies have highlighted the potential of composite scores such as the DAPSA for assessing peripheral arthritis in axSpA and pSpA. However, the swollen…
Abstract Number: 2367 • ACR Convergence 2025
Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe
Philip J. Mease¹, Andrew Ostor², Christopher Saffore³, Xiaolan Ye⁴, Manish Patel⁵, Ana Biljan⁶, Ralph Lippe⁵, Molly Edwards⁷, Iwan Armstrong⁷ and Xenofon Baraliakos⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Australian National University, Canberra, Australia, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc., Mettawa, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Buffalo Grove, IL, ⁷Adelphi Real World, Bollington, United Kingdom, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial involvement is a clinically relevant manifestation of psoriatic arthritis (PsA) that can influence management strategies. Evidence on the real-world effectiveness of advanced therapies,…
Abstract Number: 2690 • ACR Convergence 2025
Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
Lihi Eder¹, Sohan Shahab², Sarah Hopkins Gillespie³, Laura Bumbulis⁴, Helen Emanoilidis⁵, Charlene Compher⁶, Jose Scher⁷, Dafna D. Gladman⁸, Richard Cook⁴, Vinod Chandran¹ and Alexis Ogdie⁹, ¹University of Toronto, Toronto, ON, Canada, ²Women’s College Research Institute, Women’s College Hospital, Toronto, Canada, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Waterloo, Waterloo, Canada, ⁵Women’s College Hospital, Toronto, Canada, ⁶University of Pennsylvania School of Nursing and Hospital of the University of Pennsylvania, Philadelphia, ⁷New York University School of Medicine, New York, NY, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: The Dietary Interventions in Psoriatic Arthritis (DIPSA) study is a multicentre randomized controlled trial (RCT) designed to evaluate the efficacy of two personalized dietary…
Abstract Number: 0112 • ACR Convergence 2025
Proteome-wide Mendelian Randomization Identifies Therapeutic Targets in Psoriatic Arthritis
Quan Li¹ and Proton Rahman², ¹University of Toronto, Toronto, Canada, ²Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada
Background/Purpose: While numerous proteins have been linked to psoriatic arthritis (PsA), the causal nature of these associations remains unconfirmed. This study aims to employ a…
Abstract Number: 0529 • ACR Convergence 2025
Anti-PeptidylArginine Deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis
Ana-Maria Orbai¹, Hong Wang², Maria Grecu³, Ning Meng⁴, Ji Soo Kim⁵, Clifton Bingham⁴, Uzma Haque², John Miller⁴, Felipe Andrade², Erika Darrah⁶ and Eleni Tiniakou⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³River Hill High School, Clarksville, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD, ⁶Astra Zeneca, Gaithersburg, MD, ⁷UT Health Science Houston, Houston, TX
Background/Purpose: Citrullinated cathelicidin (LL37), a human-derived antimicrobial peptide, is an autoantigen in psoriatic arthritis (PsA).1 LL37 citrullination by peptidylarginine deiminase (PAD) enzymes attenuates immune activation…
Abstract Number: 0557 • ACR Convergence 2025
Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
Lihi Eder¹, Axel Hueber², Lucia Novelli³, Tianming Gao³, Jayne Stigler⁴, Zhiyuan Du³, Rodrigo García Salinas⁵, Grace Wright⁶ and Sofia Ramiro⁷, ¹University of Toronto, Toronto, ON, Canada, ²Klinikum Nuernberg, Nuernberg, Germany, ³AbbVie, North Chicago, IL, ⁴AbbVie, Round Lake, IL, ⁵Hospital Italiano La Plata, La Plata, Argentina, ⁶Grace C Wright MD PC, New York, NY, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Biologic sex can impact both clinical phenotype and therapeutic response in PsA.1–3 Previous studies have suggested that male patients (pts) may achieve better treatment…
Abstract Number: 0581 • ACR Convergence 2025
Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Philip J. Mease¹, Álvaro González Cantero², Jennifer Soung³, April Armstrong⁴, Joseph F Merola⁵, Fabian Proft⁶, Laure Gossec⁷, Dafna D. Gladman⁸, Laura Coates⁹, Lichen Teng¹⁰, Jimena Vázquez¹¹, Cynthia Deignan¹² and Arthur Kavanaugh¹³, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Dermatology, Ramón y Cajal University Hospital, Madrid, Spain, ³Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁴University of California Los Angeles, Los Angeles, ⁵Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Sorbonne Université, Pitié Salpêtrière Hospital, Paris, France, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ¹⁰Amgen Inc., Thousand Oaks, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Amgen, Inc., Agoura Hills, CA, ¹³University of California, San Diego, School of Medicine, San Diego, CA
Background/Purpose: The prevalence of cardiometabolic diseases, including obesity and diabetes, is higher in patients with psoriatic arthritis (PsA) than those without PsA.1,2 Metabolic syndrome is…
Abstract Number: 1261 • ACR Convergence 2025
Use of telemedicine to address ‘off target’ symptoms in psoriatic arthritis (PsA): implementation of PsOWell™ in PsA
Carter Pason¹, Sarah Hopkins Gillespie¹, Joelle Koplin², Rachael Hewitt³, Christine Bundy³, Ethan Craig⁴, Laura Coates⁵, Jessica A. Walsh⁶ and Alexis Ogdie⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Penn Medicine, Philadelphia, PA, ³University of Cardiff, Cardiff, United Kingdom, ⁴University of Pennsylvania, Wallingford, PA, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: Approximately 60-70% of patients with PsA do not reach minimal disease activity (MDA) on therapy. However, in many cases, this may not be related…

« Previous Page
1
…
7
8
9
10
11
…
93
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].